Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 870Carcinoma, Non-Small-Cell Lung 638Prostatic Neoplasms 516Multiple Myeloma 443Neoplasms 425Leukemia, Myeloid, Acute 381Lymphoma 358Melanoma 335Leukemia 335Neoplasm Metastasis 323Lung Neoplasms 308Lymphoma, Non-Hodgkin 303Leukemia, Lymphocytic, Chronic, B-Cell 301Colorectal Neoplasms 283Ovarian Neoplasms 266Pancreatic Neoplasms 249Precursor Cell Lymphoblastic Leukemia-Lymphoma 241Recurrence 240Myelodysplastic Syndromes 233Glioblastoma 212Hodgkin Disease 201Lymphoma, Large B-Cell, Diffuse 197Lymphoma, Follicular 196Brain Neoplasms 195Carcinoma, Renal Cell 190Head and Neck Neoplasms 188Squamous Cell Carcinoma of Head and Neck 186Lymphoma, Mantle-Cell 172Sarcoma 158Fallopian Tube Neoplasms 139

Interventions

tocilizumab 1Ribavirin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Has results × Respiratory Tract Infections × Clear all
NCT04377659 2025-05-28

Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection

Memorial Sloan Kettering Cancer Center

Phase 2 Terminated
9 enrolled 8 charts

COVID-19, Respiratory Tract Infections

NCT01502072 2021-02-15

Respiratory Syncytial Virus - RSV Protocol

M.D. Anderson Cancer Center

Phase 2 Completed
48 enrolled 11 charts

Neoplasms, Pneumonia, Respiratory Tract Infections, Respiratory Syncytial Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡